Investors were promised a contingent value right, or CVR, depending on the approval of three drugs Bristol Myers acquired in the deal. A CVR is a tradable security that is sometimes included in drugmaker deals when there is a high risk or reward for experimental treatment, according to Bloomberg.
According to the deal, all three drugs must be approved by set deadlines. If one drug doesn’t meet the deadline, there is no payment.
The first of the three drugs, ozanimod, has a deadline of March 25, but the FDA is postponing all nonessential meetings through April. It is unclear whether the FDA will consider a vote on the Bristol Myers drugs an essential meeting.
An analyst from Mizuho, a Tokyo-based retail banking company, told Bloomberg he still thinks the drug will meet the March 25 deadline, but that there has been “a fair deal of panic among investors.”
The value of the payout has fallen by 16 percent since the coronavirus fears began in February, according to Bloomberg.
Read the full article here.
More articles on pharmacy:
CVS, Walgreens plan to test for COVID-19 in parking lots
6 things to know about the leading drug being tested to treat COVID-19
USP panel sends revised compounding standards back for expert review
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
